Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient

Saeed, Mohamed E.M.; Drif, Assia I.; Efferth, Thomas

doi:10.21873/anticanres.15835

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main concept of our research efforts is to find cytotoxic compounds that can be used as functional food ingredients with negative side effects and that are able to bypass multidrug resistance or even provoke collateral sensitivity in resistant tumor cells [112][113][114][115]. Myricetin is a flavonoid present in tea, wine, fruits, and vegetables [116].…”

Section: Discussionmentioning

confidence: 99%

COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

et al. 2023

Self Cite

View full text Add to dashboard Cite

Chamomile tea is a popular beverage and herbal remedy with various health benefits, including antioxidant and antimicrobial activities and beneficial effects on metabolism. In this study, we investigated the inhibitory activities of secondary metabolites from Matricaria chamomile L. against COX2, an enzyme involved in inflammation and linked to cancer development. The cytotoxicity of the compounds was also evaluated on a panel of 60 cancer cell lines. Myricetin, one of the COX2-inhibiting and cytotoxic compounds in chamomile tea, was further studied to determine a proteomic expression profile that predicts the sensitivity or resistance of tumor cell lines to this compound. The expression of classical mechanisms of anticancer drug resistance did not affect the responsiveness of cancer cells to myricetin, e.g., ATP-binding cassette (ABC) transporters (ABCB, ABCB5, ABCC1, ABCG2), tumor suppressors (p53, WT1), and oncogenes (EGFR, RAS), whereas significant correlations between myricetin responsiveness and GSTP expression and cellular proliferation rates were observed. Additionally, Kaplan–Meier survival time analyses revealed that high COX2 expression is associated with a worse survival prognosis in renal clear cell carcinoma patients, suggesting a potential utility for COX2 inhibition by myricetin in this tumor type. Overall, this study provides insight into the molecular modes of action of chamomile secondary metabolites and their potential as cancer-preventive or therapeutic agents.

show abstract

Section: Discussionmentioning

confidence: 99%

COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another clinical case reported that in a patient with metastatic BC oral artesunate maintained disease stabilization for a duration of 1.5 years. Biomarker profiling revealed that carcinoembryonic antigen may be a potential target of artesunate [168]. A mechanistic study demonstrated that artesunate and dihydroartemisinin suppresses TGF-β signaling, subsequently inactivating cancer-associated fibroblasts, leading to inhibition of cancer growth and metastasis [169].…”

Section: Artesunatementioning

confidence: 99%

Role of natural products in tumor therapy from basic research and clinical perspectives

Wang,

Liu,

et al. 2024

Acta Materia Medica

View full text Add to dashboard Cite

Cancer is the leading cause of morbidity and mortality worldwide and is an important barrier to lengthening life expectancy in every country. Natural products are receiving increased attention from researchers globally and increasing numbers of natural products are approved for clinical studies involving cancer in recent years. To gain more insight into natural products that have undergone clinical trials for cancer treatment, a comprehensive search was conducted. The https://clinicaltrials.gov website was searched for relevant clinical trials and natural product information up to December 2022. The search terms included different types of cancers, such as colorectal, lung, breast, gynecologic, kidney, bladder, melanoma, pancreatic, hepatocellular, gastric and haematologic. Then, PubMed and Web of Science were searched for relevant articles up to February 2024. Hence, we listed existing clinical trials about natural products used in the treatment of cancers and discussed the preclinical and clinical studies of some promising natural products and their targets, indications, and underlying mechanisms of action. Our intent was to provide basic information to readers who are interested or majoring in natural products and obtain a deeper understanding of the progress and actions of natural product mechanisms of action.

show abstract

“…Carcinoembryonic antigen (CEA) stands out as a widely employed clinical biomarker for lung cancer, holding significant diagnostic value in lung adenocarcinoma [ 7 ]. However, its lack of specificity poses a limitation, as it can indicate the presence of various tumors, including colorectal and breast cancers, as well as benign lung diseases [ 8 , 9 ]. Consequently, relying solely on tumor biomarkers cannot furnish entirely accurate evidence for tumor diagnosis and necessitates evaluation in conjunction with diverse clinical symptoms, imaging tests, and other methodologies [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Ren,

Fei,

Qiu

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.

show abstract

Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient

Cited by 3 publications

References 0 publications

COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

Role of natural products in tumor therapy from basic research and clinical perspectives

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Contact Info

Product

Resources

About